April 2017

Letter from the Editor

April 1, 2017

Working in concert The act of collaborating with competitors, no less with companies and organizations outside of traditional “pharma,” was a concept that might have been considered heresy — until recently. Sure, there were agreements with academic centers or cross-licensing deals to capitalize on markets not accessible by in-house feet on the ground, but now […]

Upfront

April 1, 2017

Sunovion Teams up with Demi Lovato for Mental Health Documentary Sunovion Pharmaceuticals, five leading mental health advocacy organizations, and multi-platinum, Grammy-nominated singer, songwriter, and mental health advocate Demi Lovato have released Beyond Silence, a documentary film created by photographer and filmmaker Shaul Schwarz. The Be Vocal initiative encourages individuals living with mental health conditions to […]

Innovator’s Corner

April 1, 2017

Developing a New Class of Therapeutics Kevin Lee, Ph.D., CEO of Bicycle Therapeutics, talks about the company’s research to develop a new class of therapeutics using synthetic peptides, small molecules with antibody properties. The war on cancer may soon have a new treatment in its arsenal. Bicycle Therapeutics is developing a new class of therapeutics […]

HealthTech

April 1, 2017

Implant Wirelessly Supplies Power to the Brain Trend Watch: Micro Patches, Implants, and Microscopic 3D Printing Enhance Healthcare A research team at the Department of Electrical and Electronic Information Engineering at Toyohashi University of Technology has developed a wafer-level packaging technique to integrate a silicon large-scale integration (LSI) chip in a very thin film of […]

Last Word

April 1, 2017

Defining Value for Payers Kelly Wilder, Executive VP, Managing Partner, Precision for Value, discusses why the value propositions pharmaceutical companies use should change depending on the payer audience. PV: How has the payer landscape changed? WILDER: The changes in the payer space over the last 10 years have been significant. Pharma companies and those companies […]

A New Era of Collaboration

April 1, 2017

This month’s special issue examines the new era of collaboration from R&D to commercialization and the role various players have in shaping the future of the life-sciences industry. According to a recent KPMG report, the majority of the 400 U.S. chief executives surveyed say the next three years will be more critical for industries than […]

Collaborating A Necessary Component of Success

April 1, 2017

In 2009, PwC predicted that the pharma business model would evolve to a more patient-centric and collaborative approach by the year 2020. Three years from that deadline, there is plenty of evidence that the industry has started to collaborate both inside and outside of the “traditional” industry to help speed discovery and bring drugs to […]

The Influence of Nontraditional Players

April 1, 2017

Nontraditional players have recognized the tremendous opportunity that lies in the healthcare space, and are innovating with or without pharma partners to solve many of the healthcare issues that patients are dealing with. Companies such as Apple, Google, General Electric, Samsung, Microsoft, and IBM are flooding the healthcare market with innovative approaches to medicine. Nontraditional […]

R&D Partnerships

April 1, 2017

The pressure on the pharmaceutical industry to bring innovative medications to the market — as well as address issues related to access, cost, and value — is requiring new ways of doing research and development. Couple this with how quickly science is advancing and the volume of data that is being created from many sources, […]

Collaboration within the Commercialization Process

April 1, 2017

According to a recent Strategy& report about how to overcome industry obstacles with a cross-functional strategy, beyond the many external challenges that pharma is facing that require collaboration with outside partners, pharma also must address divides within its internal commercial culture in order to be successful. As an industry that has long operated through silos […]

Collaborating For Value

April 1, 2017

Changes across the healthcare industry are putting pressures on pharmaceutical companies to provide value to customers and stakeholders. Analysts and executives say the industry will have to watch the intertwining of provider, payer, digital, and pharma value chains closely as we enter an era that is focused on solutions versus product and where value is […]

SHOWCASE FEATURE: Global Markets: Preparing for the Next Big Markets

April 1, 2017

According to PwC, the global pharmaceutical market will be worth almost $1.6 trillion by 2020. But with growth in mature markets slowing, a lot of the growth will come from emerging economies. In fact, according to McKinsey, emerging markets are expected to account for $190 billion in sales growth between 2015 and 2020. Already emerging […]

Global Markets

April 1, 2017

Global markets have long held the promise of a rapid growth opportunity for the pharmaceutical industry, and indeed all forecasts continue to point to emerging markets being an engine of growth in volume and value of use of medicines. A closer look reveals that uptake of innovative medicines will continue to be driven by the […]

Speak Out

April 1, 2017

At the Forefront of Drug Discovery and Development: Small to Midsize Biotech/Biopharma Companies are the Leaders of Innovation  Today, the innovators of drug discovery and development often are found in the smaller, biotech and biopharma companies around the world. According to a report from HBM Partners AG, in the past several years, more than 60% […]

FEEDBACK